BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint  TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma  Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy  FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 10, 2020
Finance

LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs

LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent...
BC Extra | Jan 7, 2020
Company News

In deal with Taiho and Astex, Merck gains another K-Ras program

A deal giving Merck rights to an oncology program targeting K-Ras could help the pharma further extend its dominance in lung cancer beyond market-leading PD-1 inhibitor Keytruda -- a therapy that has already shown effects...
BC Extra | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
BC Extra | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

Miles White will step down as CEO of Abbott Laboratories (NYSE:ABT) on March 31, after 21 years in the role while remaining executive chairman. President and COO Robert Ford, who joined the company in 1996,...
BC Extra | Oct 23, 2019
Company News

With MS approval looming, Alkermes restructures to seek sustainable profits

Alkermes expects cost savings from a newly announced restructuring, combined with payments due to the company upon the anticipated approval of a new MS therapy, will allow it to maintain profitability in the coming years....
BC Innovations | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BC Extra | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
Items per page:
1 - 10 of 1018